GLTO Stock Overview
A clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Galecto, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.62 |
| 52 Week High | US$23.50 |
| 52 Week Low | US$5.52 |
| Beta | 1.25 |
| 11 Month Change | -22.70% |
| 3 Month Change | -59.32% |
| 1 Year Change | -62.64% |
| 33 Year Change | -92.46% |
| 5 Year Change | n/a |
| Change since IPO | -98.50% |
Recent News & Updates
Recent updates
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?
Jan 10
Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely
May 17Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?
Feb 01Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer
Oct 19Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Oct 19Galecto GAAP EPS of -$0.67 beats by $0.02
Jul 29We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Jun 30Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?
Mar 10Galecto: Selling At Cash Value
Dec 19We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Nov 18Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Jul 07Galecto EPS misses by $0.07
May 04We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth
Mar 23Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?
Jan 29
Galecto EPS misses by $41.65
Dec 11Shareholder Returns
| GLTO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.6% | 2.5% | 2.2% |
| 1Y | -62.6% | 16.1% | 31.6% |
Return vs Industry: GLTO underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: GLTO underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| GLTO volatility | |
|---|---|
| GLTO Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLTO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GLTO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 13 | Hans Schambye | galecto.com |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Galecto, Inc. Fundamentals Summary
| GLTO fundamental statistics | |
|---|---|
| Market cap | US$7.40m |
| Earnings (TTM) | -US$21.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs GLTO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLTO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$21.17m |
| Earnings | -US$21.17m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GLTO perform over the long term?
See historical performance and comparison